Intravitreal DEX implants (Ozurdex) offer a longer duration of action compared to anti-VEGF agents, typically requiring reinjection every 4 to 6 months, depending on the individual patient’s response and recurrence of macular edema [10,15]. This evidence concerns the gene VEGFA and macular retinal edema.